Objective:

To develop a reproducible 40 Hz vibrotactile stimulation (VTS) platform for in vitro models of Alzheimer’s disease (AD), benchmark its effects across neuronal, vascular, and immune systems, and assess its potential for medical device development.

Background:

Gamma-frequency stimulation has shown therapeutic promise in AD, but translation requires standardized delivery methods with validated cellular effects. Vibrotactile approaches offer a safe, noninvasive route that could be developed into a clinically deployable medical device.

Design/Methods:

A sinusoidal 40 Hz waveform was amplified to drive a vibration actuator (8.6 Ω, ≤1 W). Output voltage stability was verified using an oscilloscope. The platform was applied to: (1) SH-SY5Y neurons exposed to Aβ for analysis of viability, autophagy, and tau phosphorylation; (2) primary human pericytes exposed to Aβ for intracellular Ca²⁺ measurement using Fura-2; and (3) BV2 microglia treated with LPS for cytokine profiling, morphology, and stress-kinase signaling.

Results:

The device delivered stable 40 Hz stimulation within defined safety parameters. Biological effects included improved neuronal survival, enhanced autophagy, and reduced tau hyperphosphorylation; normalization of Aβ-induced Ca²⁺ overload in pericytes; and suppression of LPS-induced cytokine expression and JNK activation in microglia.

Conclusions: